| Mapping the human genetic architecture of COVID-19 CHG Initiative Nature, 2021 | 721* | 2021 |
| The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic TCHG Initiative European Journal of Human Genetics, 2020 | 459 | 2020 |
| An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol … G Darcis, A Kula, S Bouchat, K Fujinaga, F Corazza, A Ait-Ammar, ... PLoS pathogens 11 (7), e1005063, 2015 | 297 | 2015 |
| Whole genome sequencing reveals host factors underlying critical Covid-19 Nature, 2022 | 222 | 2022 |
| HIV latency: should we shock or lock? G Darcis, B Van Driessche, C Van Lint Trends in immunology 38 (3), 217-228, 2017 | 183 | 2017 |
| Reactivation of simian immunodeficiency virus reservoirs in the brain of virally suppressed macaques L Gama, CM Abreu, EN Shirk, SL Price, M Li, GM Laird, KAM Pate, ... Aids 31 (1), 5-14, 2017 | 163 | 2017 |
| Current status of latency reversing agents facing the heterogeneity of HIV-1 cellular and tissue reservoirs A Ait-Ammar, A Kula, G Darcis, R Verdikt, S De Wit, V Gautier, ... Frontiers in microbiology 10, 3060, 2020 | 145 | 2020 |
| Epigenetic control of HIV-1 post integration latency: implications for therapy A Kumar, G Darcis, C Van Lint, G Herbein Clinical epigenetics 7, 1-12, 2015 | 106 | 2015 |
| Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality T Nakanishi, S Pigazzini, F Degenhardt, M Cordioli, G Butler-Laporte, ... The Journal of clinical investigation 131 (23), 2021 | 101 | 2021 |
| Sequential treatment with 5‐aza‐2′‐deoxycytidine and deacetylase inhibitors reactivates HIV‐1 S Bouchat, N Delacourt, A Kula, G Darcis, B Van Driessche, F Corazza, ... EMBO molecular medicine 8 (2), 117-138, 2016 | 101 | 2016 |
| A first update on mapping the human genetic architecture of COVID-19 CHG Initiative Nature 608, 2022 | 92* | 2022 |
| Two‐drug vs. three‐drug combinations for HIV‐1: Do we have enough data to make the switch? S Moreno, CF Perno, PW Mallon, G Behrens, P Corbeau, JP Routy, ... HIV medicine 20, 2-12, 2019 | 75 | 2019 |
| The quest for cellular markers of HIV reservoirs: any color you like G Darcis, B Berkhout, AO Pasternak Frontiers in immunology 10, 485847, 2019 | 63 | 2019 |
| Transmission of SARS-CoV-2 after COVID-19 screening and mitigation measures for primary school children attending school in Liège, Belgium C Meuris, C Kremer, A Geerinck, M Locquet, O Bruyère, J Defêche, ... JAMA network open 4 (10), e2128757-e2128757, 2021 | 56 | 2021 |
| The molecular biology of HIV latency G Khoury, G Darcis, MY Lee, S Bouchat, B Van Driessche, DFJ Purcell, ... HIV vaccines and cure: the path towards finding an effective cure and …, 2018 | 51 | 2018 |
| Novel genes and sex differences in COVID-19 severity R Cruz, S Diz-de Almeida, M López de Heredia, I Quintela, FC Ceballos, ... Human Molecular Genetics 31 (22), 3789-3806, 2022 | 50 | 2022 |
| Long-term clinical follow-up of patients suffering from moderate-to-severe COVID-19 infection: a monocentric prospective observational cohort study G Darcis, A Bouquegneau, N Maes, M Thys, M Henket, F Labye, ... International Journal of Infectious Diseases 109, 209-216, 2021 | 50 | 2021 |
| CD32+ CD4+ T cells are highly enriched for HIV DNA and can support transcriptional latency G Darcis, NA Kootstra, B Hooibrink, T van Montfort, I Maurer, K Groen, ... Cell reports 30 (7), 2284-2296. e3, 2020 | 50 | 2020 |
| The current status of latency reversing agents for HIV-1 remission A Rodari, G Darcis, CM Van Lint Annual review of virology 8, 491-514, 2021 | 48 | 2021 |
| Factors associated with late presentation for HIV care in a single Belgian reference center: 2006–2017 G Darcis, I Lambert, AS Sauvage, F Frippiat, C Meuris, F Uurlings, ... Scientific Reports 8 (1), 8594, 2018 | 46 | 2018 |
